Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole

Bertrand Nyuykonge, Wilson Lim, Lukas van Amelsvoort, Alexandro Bonifaz, Ahmed Fahal, Hamid Badali, Mahdi Abastabar, Annelies Verbon, Wendy van de Sande*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
33 Downloads (Pure)


Introduction: Eumycetoma is a subcutaneous mutilating disease that can be caused by many different fungi. Current treatment consists of prolonged itraconazole administration in combination with surgery. In many centres, due to their slow growth rate, the treatment for eumycetoma is often started before the causative agent is identified. This harbours the risk that the causative fungus is not susceptible to the given empirical therapy. In the open-source drug program MycetOS, ravuconazole and luliconazole were promising antifungal agents that were able to inhibit the growth of Madurella mycetomatis, the most common causative agent of mycetoma. However, it is currently not known whether these drugs inhibit the growth of other eumycetoma causative agents. Materials and methods: Here, we determined the in vitro activity of luliconazole, lanoconazole and ravuconazole against commonly encountered eumycetoma causative agents. MICs were determined for lanoconazole, luliconazole and ravuconazole against 37 fungal isolates which included Madurella species, Falciformispora senegalensis, Medicopsis romeroi and Trematosphaeria grisea and compared to those of itraconazole. Results: Ravuconazole, luliconazole and lanoconazole showed high activity against all eumycetoma causative agents tested with median minimal inhibitory concentrations (MICs) ranging from 0.008–2 µg/ml, 0.001–0.064 µg/ml and 0.001–0.064 µg/ml, respectively. Even Ma. fahalii and Me. romeroi, which are not inhibited in growth by itraconazole at a concentration of 4 µg/ml, were inhibited by these azoles. Conclusion: The commonly encountered eumycetoma causative agents are inhibited by lanoconazole, luliconazole and ravuconazole. These drugs are promising candidates for further evaluation as potential treatment for eumycetoma.

Original languageEnglish
Pages (from-to)650-655
Number of pages6
Issue number6
Early online date10 Apr 2022
Publication statusPublished - Jun 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Mycoses published by Wiley-VCH GmbH.


Dive into the research topics of 'Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole'. Together they form a unique fingerprint.

Cite this